Inge Dierynck

TL;DR: Once-daily darunavir/ritonavir was both statistically noninferior and superior in virologic response to LPV/r, with a more favorable gastrointestinal and lipid profile, confirming DRV/ r as an effective, well tolerated, and durable option for antiretroviral-naive patients.

TL;DR: Investigating the impact of PI resistance-associated mutations on the protease binding of five PIs used clinically provided a mechanistic explanation for darunavir's potent antiviral activity and high genetic barrier to the development of resistance.

TL;DR: In treatment-experienced, LPV-naive patients, the overall virologic failure rate in the DRV/r arm was low and was associated with limited resistance development, showing that the use of DRv/r in earlier lines of treatment was less likely to lead to cross-resistance to other protease inhibitors compared with LPV/ r.

TL;DR: It is demonstrated that antigen-specific Nanobodies of sub-micromolar affinity and stability above 30 kJ/mol, at a titer of 10(-4) can be retrieved in a single-step selection.

TL;DR: In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response.